{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:10:47Z","timestamp":1791616247149,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014126","name":"GE Global Research","doi-asserted-by":"publisher","award":["A-71 AM003"],"award-info":[{"award-number":["A-71 AM003"]}],"id":[{"id":"10.13039\/100014126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11351-4","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:03:09Z","timestamp":1738044189000},"page":"4417-4428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Natalie","family":"Wiley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mladen","family":"Zecevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Stolzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik V.","family":"Soloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-7272","authenticated-orcid":false,"given":"Carolyn L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"11351_CR1","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1007\/s00330-020-07426-z","volume":"31","author":"S Thiravit","year":"2021","unstructured":"Thiravit S, Brunnquell C, Cai LM et al (2021) Use of dual-energy CT for renal mass assessment. Eur Radiol 31:3721\u20133733. https:\/\/doi.org\/10.1007\/s00330-020-07426-z","journal-title":"Eur Radiol"},{"key":"11351_CR2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1007\/s00330-016-4597-7","volume":"27","author":"K Hellbach","year":"2017","unstructured":"Hellbach K, Sterzik A, Sommer W et al (2017) Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer. Eur Radiol 27:2532\u20132537. https:\/\/doi.org\/10.1007\/s00330-016-4597-7","journal-title":"Eur Radiol"},{"key":"11351_CR3","doi-asserted-by":"publisher","unstructured":"Ahnfelt A, Dahlman P, Segelsj\u00f6 M, Magnusson MO, Magnusson A (2022) Accuracy of iodine quantification using dual-energy computed tomography with focus on low concentrations. Acta Radiol 63:623\u2013631. https:\/\/doi.org\/10.1177\/02841851211009462","DOI":"10.1177\/02841851211009462"},{"key":"11351_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejrad.2018.02.019","volume":"101","author":"SR Hong","year":"2018","unstructured":"Hong SR, Hur J, Moon YW et al (2018) Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. Eur J Radiol 101:118\u2013123. https:\/\/doi.org\/10.1016\/j.ejrad.2018.02.019","journal-title":"Eur J Radiol"},{"key":"11351_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2214\/AJR.21.26911","volume":"218","author":"A Drljevic-Nielsen","year":"2022","unstructured":"Drljevic-Nielsen A, Donskov F, Mains JR et al (2022) Prognostic utility of parameters derived from pretreatment dual-layer spectral-detector CT in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol 218:867\u2013876. https:\/\/doi.org\/10.2214\/AJR.21.26911","journal-title":"AJR Am J Roentgenol"},{"key":"11351_CR6","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.3390\/ijms20112674","volume":"20","author":"M Frelaut","year":"2019","unstructured":"Frelaut M, Le Tourneau C, Borcoman E (2019) Hyperprogression under immunotherapy. Int J Mol Sci 20:2674. https:\/\/doi.org\/10.3390\/ijms20112674","journal-title":"Int J Mol Sci"},{"key":"11351_CR7","doi-asserted-by":"publisher","first-page":"9139","DOI":"10.2147\/CMAR.S218756","volume":"12","author":"Q Durrechou","year":"2020","unstructured":"Durrechou Q, Domblides C, Sionneau B et al (2020) Management of immune checkpoint inhibitor toxicities. Cancer Manag Res 12:9139. https:\/\/doi.org\/10.2147\/CMAR.S218756","journal-title":"Cancer Manag Res"},{"key":"11351_CR8","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"11351_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38837-3","volume":"14","author":"E Garralda","year":"2023","unstructured":"Garralda E, Laurie SA, Seymour L, De Vries EGE (2023) Towards evidence-based response criteria for cancer immunotherapy. Nat Commun 14:3001. https:\/\/doi.org\/10.1038\/s41467-023-38837-3","journal-title":"Nat Commun"},{"key":"11351_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","volume":"16","author":"W Jia","year":"2019","unstructured":"Jia W, Gao Q, Han A et al (2019) The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med 16:655\u2013670. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2019.0144","journal-title":"Cancer Biol Med"},{"key":"11351_CR11","doi-asserted-by":"publisher","first-page":"e2034020","DOI":"10.1001\/jamanetworkopen.2020.34020","volume":"4","author":"AK Green","year":"2021","unstructured":"Green AK (2021) Challenges in assessing the cost-effectiveness of cancer immunotherapy. JAMA Netw Open 4:e2034020. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.34020","journal-title":"JAMA Netw Open"},{"key":"11351_CR12","doi-asserted-by":"publisher","unstructured":"Nishino M (2018) Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond. Am Soc Clin Oncol Educ Book 38:1019\u20131029. https:\/\/doi.org\/10.1200\/EDBK_201441","DOI":"10.1200\/EDBK_201441"},{"key":"11351_CR13","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.3390\/cancers15245873","volume":"15","author":"K Bekku","year":"2023","unstructured":"Bekku K, Kawada T, Sekito T et al (2023) The diagnosis and treatment approach for oligo-recurrent and oligo-progressive renal cell carcinoma. Cancers 15:5873. https:\/\/doi.org\/10.3390\/cancers15245873","journal-title":"Cancers"},{"key":"11351_CR14","doi-asserted-by":"publisher","first-page":"1276729","DOI":"10.3389\/fonc.2023.1276729","volume":"13","author":"K Khaddour","year":"2023","unstructured":"Khaddour K, Zhou A, Butt O et al (2023) Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and Merkel cell carcinoma. Front Oncol 13:1276729. https:\/\/doi.org\/10.3389\/fonc.2023.1276729","journal-title":"Front Oncol"},{"key":"11351_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"James Larkin","year":"2015","unstructured":"Larkin James, Chiarion-Sileni Vanna, Gonzalez Rene et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"11351_CR16","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/cncr.34180","volume":"128","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, McDermott DF, Escudier B et al (2022) Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 128:2085\u20132097. https:\/\/doi.org\/10.1002\/cncr.34180","journal-title":"Cancer"},{"key":"11351_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"11351_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3348\/kjr.2013.14.1.13","volume":"14","author":"SK Jeh","year":"2013","unstructured":"Jeh SK, Kim SH, Kang BJ (2013) Comparison of the diagnostic performance of response evaluation criteria in solid tumor 1.0 with response evaluation criteria in solid tumor 1.1 on MRI in advanced breast cancer response evaluation to neoadjuvant chemotherapy. Korean J Radiol 14:13\u201320. https:\/\/doi.org\/10.3348\/kjr.2013.14.1.13","journal-title":"Korean J Radiol"},{"key":"11351_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2214\/AJR.16.16895","volume":"209","author":"P Liang","year":"2017","unstructured":"Liang P, Ren X, Gao J et al (2017) Iodine concentration in spectral CT: assessment of prognostic determinants in patients with gastric adenocarcinoma. AJR Am J Roentgenol 209:1033\u20131038. https:\/\/doi.org\/10.2214\/AJR.16.16895","journal-title":"AJR Am J Roentgenol"},{"key":"11351_CR20","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.ejrad.2016.03.030","volume":"85","author":"X Li","year":"2016","unstructured":"Li X, Meng X, Ye Z (2016) Iodine quantification to characterize primary lesions, metastatic and non-metastatic lymph nodes in lung cancers by dual energy computed tomography: an initial experience. Eur J Radiol 85:1219\u20131223. https:\/\/doi.org\/10.1016\/j.ejrad.2016.03.030","journal-title":"Eur J Radiol"},{"key":"11351_CR21","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1002\/1097-0258(20001130)19:223.0.co;2-f","volume":"19","author":"TJ Cole","year":"2000","unstructured":"Cole TJ (2000) Sympercents: symmetric percentage differences on the 100 loge scale simplify the presentation of log transformed data. Stat Med 19:3109\u20133125. https:\/\/doi.org\/10.1002\/1097-0258(20001130)19:223.0.co;2-f","journal-title":"Stat Med"},{"key":"11351_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837. https:\/\/doi.org\/10.2307\/2531595","journal-title":"Biometrics"},{"key":"11351_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2967\/jnumed.119.237891","volume":"61","author":"S L\u00fctje","year":"2020","unstructured":"L\u00fctje S, Feldmann G, Essler M et al (2020) Immune checkpoint imaging in oncology: a game changer toward personalized immunotherapy? J Nucl Med 61:1137\u20131144. https:\/\/doi.org\/10.2967\/jnumed.119.237891","journal-title":"J Nucl Med"},{"key":"11351_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/biomedicines11041071","volume":"11","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa F, di Meo N, Rutigliano M et al (2023) Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice. Biomedicines 11:1071","journal-title":"Biomedicines"},{"key":"11351_CR25","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"11351_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753\u20131759. https:\/\/doi.org\/10.1200\/JCO.2006.07.3049","journal-title":"J Clin Oncol"},{"key":"11351_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"11351_CR28","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ejrad.2015.06.001","volume":"84","author":"WM Thaiss","year":"2015","unstructured":"Thaiss WM, Sauter AW, Bongers M et al (2015) Clinical applications for dual energy CT versus dynamic contrast enhanced CT in oncology. Eur J Radiol 84:2368\u20132379. https:\/\/doi.org\/10.1016\/j.ejrad.2015.06.001","journal-title":"Eur J Radiol"},{"key":"11351_CR29","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00330-014-3223-9","volume":"24","author":"J Baxa","year":"2014","unstructured":"Baxa J, Vondr\u00e1kov\u00e1 A, Matou\u0161kov\u00e1 T et al (2014) Dual-phase dual-energy CT in patients with lung cancer: assessment of the additional value of iodine quantification in lymph node therapy response. Eur Radiol 24:1981\u20131988. https:\/\/doi.org\/10.1007\/s00330-014-3223-9","journal-title":"Eur Radiol"},{"key":"11351_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00579-2","volume":"23","author":"Z Alizzi","year":"2023","unstructured":"Alizzi Z, Gogbashian A, Karteris E, Hall M (2023) Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study. Cancer Imaging 23:62. https:\/\/doi.org\/10.1186\/s40644-023-00579-2","journal-title":"Cancer Imaging"},{"key":"11351_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2214\/AJR.21.26636","volume":"218","author":"M Meyer","year":"2022","unstructured":"Meyer M, Hohenberger P, Overhoff D et al (2022) Dual-energy CT vital iodine tumor burden for response assessment in patients with metastatic GIST undergoing TKI therapy: comparison with standard CT and FDG PET\/CT criteria. AJR Am J Roentgenol 218:659\u2013669. https:\/\/doi.org\/10.2214\/AJR.21.26636","journal-title":"AJR Am J Roentgenol"},{"key":"11351_CR32","doi-asserted-by":"publisher","first-page":"102156","DOI":"10.1016\/j.eclinm.2023.102156","volume":"63","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Pan Q, Lu M, Zhao B (2023) Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials. eClinicalMedicine 63:102156. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102156","journal-title":"eClinicalMedicine"},{"key":"11351_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.annonc.2022.04.450","volume":"33","author":"J Luo","year":"2022","unstructured":"Luo J, Wu S, Rizvi H et al (2022) Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol 33:824\u2013835. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.450","journal-title":"Ann Oncol"},{"key":"11351_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10555-021-09970-6","volume":"40","author":"S Saxena","year":"2021","unstructured":"Saxena S, Singh RK (2021) Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity. Cancer Metastasis Rev 40:447\u2013476. https:\/\/doi.org\/10.1007\/s10555-021-09970-6","journal-title":"Cancer Metastasis Rev"},{"key":"11351_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/modpathol.2017.104","volume":"31","author":"L Cheng","year":"2018","unstructured":"Cheng L, Lopez-Beltran A, Massari F et al (2018) Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol 31:24\u201338. https:\/\/doi.org\/10.1038\/modpathol.2017.104","journal-title":"Mod Pathol"},{"key":"11351_CR36","doi-asserted-by":"publisher","unstructured":"Stinauer MA, Kavanagh BD, Schefter TE et al (2011) Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 6:34. https:\/\/doi.org\/10.1186\/1748-717X-6-34","DOI":"10.1186\/1748-717X-6-34"},{"key":"11351_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctro.2017.09.002","volume":"6","author":"RS Youland","year":"2017","unstructured":"Youland RS, Blanchard ML, Dronca R et al (2017) Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clin Transl Radiat Oncol 6:25\u201330. https:\/\/doi.org\/10.1016\/j.ctro.2017.09.002","journal-title":"Clin Transl Radiat Oncol"},{"key":"11351_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/mmt-2016-0018","volume":"4","author":"R Tyrell","year":"2017","unstructured":"Tyrell R, Antia C, Stanley S, Deutsch GB (2017) Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. Melanoma Manag 4:61\u201368. https:\/\/doi.org\/10.2217\/mmt-2016-0018","journal-title":"Melanoma Manag"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11351-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:16:04Z","timestamp":1751544964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11351-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["11351"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11351-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Dr. Carolyn Wang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: GE Healthcare (for the research grant).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (Mladen Zecevic MS) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Study subjects or cohorts have not been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}